Ackman Left Out In The Cold By Allergan, Letter Claims
This article was originally published in The Pink Sheet Daily
Activist investor Bill Ackman portrays Allergan CEO David Pyott as only having his personal interest at heart, while failing to acknowledge his own motives in working with Valeant, in an open letter to the Botox-maker.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.